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Abstract
While abnormalities related to carbohydrates (glycans) are frequent for patients with
rare and undiagnosed diseases as well as in many common diseases, these glycan-
related phenotypes (glycophenotypes) are not well represented in knowledge bases
(KBs). If glycan-related diseases were more robustly represented and curated with
glycophenotypes, these could be used for molecular phenotyping to help to realize the
goals of precision medicine. Diagnosis of rare diseases by computational cross-species
comparison of genotype–phenotype data has been facilitated by leveraging ontological
representations of clinical phenotypes, using Human Phenotype Ontology (HPO), and
model organism ontologies such asMammalian PhenotypeOntology (MP) in the context
of the Monarch Initiative. In this article, we discuss the importance and complexity
of glycobiology and review the structure of glycan-related content from existing KBs
and biological ontologies. We show how semantically structuring knowledge about the
annotation of glycophenotypes could enhance disease diagnosis, and propose a solution
to integrate glycophenotypes and related diseases into the Unified Phenotype Ontology
(uPheno), HPO, Monarch and other KBs. We encourage the community to practice good
D
ow
nloaded from
 https://academ
ic.oup.com
/database/article-abstract/doi/10.1093/database/baz114/5626543 by Jackson Laboratory user on 19 N
ovem
ber 2019
Page 2 of 18 Database, Vol. 2019, Article ID baz114
identifier hygiene for glycans in support of semantic analysis, and clinicians to add
glycomics to their diagnostic analyses of rare diseases.
Introduction
From antiquity to present days, clinicians have described
diseases with phenotypic features mostly in a free-text
representation—from ancient Egyptians using papyrus (1)
to today’s disease descriptions in textbooks, publications
or medical records. However, with the advance of bioinfor-
matics methods and standards, phenotypes are increasingly
being codified in a computable format using ontologies (2).
An ontology provides logical classifications of terms in a
specified domain and the relationships between them. It also
bears textual and logical definitions, synonyms identifiers
and cross-references to other ontologies, databases (DB)
and knowledge bases (KB) (3). The Open Biological and
Biomedical Ontology (OBO) Foundry has developed stan-
dards for logically well-formed and interoperable ontolo-
gies respectful of the representations of biological reality
(4). These ontologies are often used in KBs and DBs to
semantically structure information and allow for compu-
tational classification and inferencing across data.
Biomedical phenotype and disease ontologies have been
used in precisionmedicine for ‘deep phenotyping’ (5),which
is ‘the precise and comprehensive analysis of phenotypic
abnormalities in which the individual components of the
phenotype are observed and described’ (6). The Human
Phenotype Ontology (HPO) (7) is one of the leading
biomedical phenotype ontologies and is used by various
European and American national rare disease efforts and
clinical databases such as 100,000 Genomes Project (8),
ClinGen (9), Orphanet (10) and ClinVar (11). The HPO is
a source of computable phenotypic descriptions that can
support the differential diagnosis process. For example, a
set of HPO-encoded phenotypes from a patient with an
undiagnosed disease can be compared with the phenotypes
of known diseases using semantic similarity algorithms
for disease diagnostics (7, 12–15). The HPO is a part of
a reconciliation effort to align the logical representation
of phenotypes across species (7), which enables their
integration into a common, species-independent resource
called the Unified Phenotype Ontology (uPheno) (16).
These resources provide the basis of semantic similarity
algorithms implemented within variant prioritization
tools such as the program Exomiser developed by the
Monarch Initiative team (14, 17), which uses a protein-
interaction network approach to help prioritize variants
based on interaction partners (18–20). The Monarch
Initiative (monarchinitiative.org) provides ontology-based
tools for clinical and translational research applications
(12–14). The Monarch platform uses the Mondo Disease
Ontology that provides a harmonized and computable
foundation for associating phenotypes to diseases (21, 22).
Mondo integrates the existing sources of disease definitions,
including the Disease Ontology (23), the National Cancer
Institute Thesaurus (NCIt) (24), the Online Mendelian
Inheritance in Man (OMIM) (25), Systematized Nomen-
clature of Medicine–Clinical Terms (SNOMED CT) (26),
International Classification of Diseases (27), International
Classification of Diseases for Oncology (28), OncoTree
(29), MedGen (30) and numerous others into a single,
coherent merged ontology.Mondo is co-developed with the
HPO, to ensure comprehensive representation of diseases
and phenotypes.
Use of semantic deep phenotyping approaches has been
particularly valuable in cases, where a strictly sequence-
based analysis has been insufficient to lead to a diagnosis.
This is often the case with patients admitted to national and
regional undiagnosed clinics, such as the National Institutes
of Health (NIH), Undiagnosed Diseases Program (UDP)
and Network (UDN), where only 28% of UDN patients
have been diagnosed to date (31). One of the most interest-
ing characteristics of patients in these programs is the high
incidence of glycan-related molecular defects, which we
refer to here as ‘glycophenotypes’. These include observable
abnormalities in the structure, abundance, distribution and
activity of glycans, as found in their free or conjugated
forms. For example, Gall et al. (32) reported that 50% of
patients admitted to the UDP had abnormal glycopheno-
types,whether the causal genes were related to glycobiology
or not (33). While diseases related to glycobiology have
been well-studied (34–36), the integration of glycomics
data and glycophenotypes into biological KBs lags behind
what we see for genomic, proteomic and metabolomic data
(key biological entity types like genes, diseases, pathways,
etc.); hence, ‘the need of informatics in glycobiology’ as
Campbell et al. state: ‘Databases that provide authoritative
information about glycan and glycoconjugate structures,
andwell-defined standards that allow this information to be
exchanged, are required as a foundation for computational
tools that give insight into the biological functions and
consequences of glycosylation (37)’.
Despite the diagnostic and informatics success of HPO,
glycophenotypes are underrepresented in this resource and,
thus, limit their value in differential diagnosis. For instance,
patients with fucosidosis can have at least five glycophe-
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Figure 1. An example of classification of relevant glycans involved in human diseases based on the essential of glycobiology and CHEBI ontology.
Glycans can be free or conjugated to macromolecules (protein, lipids). Free glycans can be monosaccharides (n =1), oligosaccharides (2<n<10) or
polysaccharides (n> 10), and their derivatives (e.g. acetylated, sulfated) 13 exemplary diseases names along with the mutated genes and MONDO
ID (in parentheses) are indicated for 13 classes of glycans. Up, down orange arrows and orange equal signs indicate, respectively, the involvement
of the gene products in glycan biosynthesis, degradation or transport. Based on our disease curation, there are 176 glycan-related diseases (CDG
and diseases in which glycophenotypes are detectable, see online supplementary material for Table S1).
notypes such as decrease of fucosidase activity, urinary
glycosaminoglycan excretion, oligosacchariduria, increase
of urinary glycopeptides and accumulation of glycolipids
expressing blood group antigens in the liver (38, 39), but
only two of these glycophenotypes are in HPO (40, 41).
In addition to phenotypes related to glycan-binding pro-
tein (GBP) staining, there can be potentially at least six
glycophenotypes per glycan-related diseases, hence, 1056
possible HPO glycophenotypes terms for the 176 glycan
related diseases (congenital disorder of glycosylation (CDG)
and diseases where glycophenotypes are detectable, see
online supplementary material for Table S1). Neverthe-
less, there are only 126 HPO terms related to glycobiol-
ogy as of time of writing, which are either subclasses of
abnormal glucose homeostasis (38/126), abnormal glyco-
sylation (46/126 whether glycolipid metabolism or pro-
tein glycosylation), abnormal glycosyltransferases activity
(4/126) and abnormal free glycans (38/126), (see online
supplementary material for Table S2). In addition, these
existing HPO glycophenotypes occupy only 5/20 categories
of glycans indicated in Figure 1 (glycosyltransferases and
GBP phenotypes excluded). Finally, within Monarch plat-
form, the term ‘abnormal glycosylation’ (HP:0012345) is
associated with 31 diseases (42) and the term ‘glycan’
returns only 17 phenotypes (43), yet according to Freeze
et al. (34) and Ferreira (44), 130–134 CDG exist (non-
including other glycan-related diseases such as diseases
related to GBP). Furthermore, Xia et al. (36) reported
54 different urinary glycophenotypes for 10 glycan-related
diseases.
Here, we provide a short overview of glycobiology, its
importance in health and disease and a discussion of some
of the technological and informatics challenges that face
the use of these data for disease discovery research and
diagnostics. We demonstrate the utility in adding glycophe-
notypes to disease diagnostic pipelines. Finally, we present
the results of surveying a selection of ontologies and KBs
based on an updated list of glycoscience-related informatics
resources from Campbell et al. (37).
Glycans: A Galactic Odyssey
Structures and classification
Glycans, also referred to as carbohydrates and sugars (45),
are a fundamental class of biomolecules with the general
chemical formula CnH2nOn. They are among the oldest
organic molecules found in the Milky Way, and one of the
simplest glycans, glycoladehyde, was even discovered on the
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molecular cloud Sagittarius B2 (46). Glycans, along with
amines, may have enriched our solar system to influence
life on Earth (47), possibly during meteorite collisions on
planet Earth, which led to the formation of more organic
molecules (48).
Glycans can be found in bacteria, archaea, eukaryotes
and most viruses (49). They are the most abundant
biomolecules on Earth with plant-synthesized cellulose
(50). In eukaryotic cells, glycans can be found in free forms
(monosaccharides, oligosaccharides and polysaccharides)
or as bioconjugates, covalently attached to the other
major classes of biomolecules such as nucleic acids
(sugar-nucleotides), proteins (glycoproteins with N-linked
glycans (N-glycans) and O-linked-glycans (O-glycans),
glycosylphosphatidylinositol-anchored, proteoglycans) and
lipids (lipid-linked oligosaccharides, glycosphingolipids,
glycosylphosphatidylinositol-anchored) (Figure 1).
Glycans can be N-acetylated (e.g. N-acetylglucosamine
or GlcNAc), phosphorylated (e.g. glucose-6-phosphate),
sulfated (e.g. heparan sulfate [HS]), etc. The collection
of all glycans in an organism, the glycome, displays an
extreme diversity of structures, amounting to up to 104
times more molecules than those found in the proteome
(51). The molecular weight of glycans can range from
60 with glycoladehyde (46) to more than 2×106 Daltons
(Da),with glycan polymers such as hyaluronan (52)making
them only partially accessible to metabolomics studies, as
metabolomics focuses on the study of molecules below
1,500 Da (53). Glycans, although often regarded at the
periphery of metabolomics, proteomics and lipidomics, can
play crucial roles in cell biology.
Glycan Roles in Human Biology
Given their ancient evolutionary history, diversity and
abundance, it is not surprising that glycans play a pivotal
role in human biology. Glycans play many roles that range
from structural, modulatory to recognition (49) (Table 1).
In terms of structural role, glycans can be a physical barrier,
assist protein folding and serve as energy storage. The
physical barrier or glycocalyx is a protective coat made
of glycoaminoglycans (e.g. HS), glycoproteins (including
GPI-anchored) and glycolipids located at the cell surface
of eukaryotic cells (54). Glycans at the cell surface and on
circulating serum proteins can also provide a shield against
proteases and against attachment to certain pathogens
(45). Glycans can help protein folding in the endoplasmic
reticulum by stabilizing and promoting interaction with
GBP (lectins) involved in protein folding such as calnexin
and calreticulin (55). Glycans can serve as a structural
energy storage with glycogen made of polymer of 55000
molecules of glucose (56).
The modulatory role of many signaling proteins depends
on their own glycosylation, the glycosylation or glycan
binding activity of their counter receptors. For instance,
human chorionic gonadotropin’s signal transduction
depends on its N-linked glycans (57). Similarly, glycans on
cell surface proteins are required for the signaling of GBP.
For instance, galectin-1 and galectin-8 will signal phos-
phatidylserine exposure on neutrophils through interaction
with polylactosamine containing counter receptors (58,
59). Finally, some receptors can be regulated by signaling
glycans such as GM3 glycolipid on the epidermal growth
factor receptor (EGFR) (60).
Glycans are involved in intrinsic and extrinsic recog-
nition (45, 49). From the initiation of spermatozoid
attachment on sialyl-Lewis(x) on the egg (61) to cell death
with glycosylation of Fas/TRAIL death receptor (62),
glycans play a role in cell recognition and in the cellular
social life, through the interaction of glycan–protein or
glycan–glycan interaction. For instance, many antigens are
glycan-based, such as the ABO blood group (63). Stem
cells growth and differentiation depend on O-fucosylation
on Notch (64), and HS is a key regulator of embryonic
fate (65). In fact, stem cells’ glycosylation profiles indicate
the stage of pluripotency, especially fucosylated glycans
(66), and are used for their isolation through specific
sets of lectins (67). In cancer biology, glycans are used as
markers for many types of cancers (68) and are involved in
resistance to cancer in naked mole rats with high molecular
weight hyaluronan (69). Glycans are also involved in
parasitic infections, during the attachment phase, whether
zoonotic (e.g. schistosome (70)), microbial (e.g. Escherichia
coli 086, bearing blood group antigen (71)) or viral (e.g.
influenza virus H1N1, where H stands for hemagglutinin
and N for neuraminidase, respectively, a lectin and a
glyco-enzyme (72)).
Glycans in Human Diseases
Alterations in glycan function, such as genetic perturbation
in synthesis (involving glycosyltransferases, chaperone of
glycosyltransferases, transporter, etc.), degradation or their
attachment through GBP, can contribute to the patho-
physiology of various diseases. For instance, mutations in
the glycosyltransferase EXT1 can lead to the formation
of abnormally short HS molecules which accumulate in
the Golgi apparatus, and cause abnormal cytoskeleton
formation (73) and increase of bone morphogenetic pro-
teins that lead to osteochondromas (74). Glycans also play
a role in molecular recognition in innate and acquired
immunity. Human milk oligosaccharides contribute to a
healthy infant gut microbiome by preventing bacteria and
viruses from binding to the intestinal mucosa (75). Bacterial
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Figure 2. Examples of glycophenotypes that can be captured from various laboratory techniques From a patient’s anatomical structures (indicated
in orange boxes, e.g. blood), glycans such as free oligosaccharides (F.O.S.) and glycan-related molecules can be analyzed by standard glycomics
assays (indicated in green boxes, e.g. GBP or antibody assay). Patients’ glycophenotypes indicated in the blue boxes can be captured from
publications: decreased circulating HS level (82), increased urinary polyhexose glycans (36), increased dermatan sulfate in the CSF (83), decreased
O-Fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity (84) and increased Tn antigen in white blood cells (85). In our preliminary work,
we have logically defined design patterns (86) that would generate hundreds of classes, but they are not yet fully integrated in the HPO.
lipopolysaccharide can stimulate innate immune responses
(76). Glycosylation of immunoglobulins (Ig) can contribute
tomanyautoimmunediseases such as IgAnephropathy (77).
In this disorder, abnormal hypoglycosylated IgA1 displays
the glycan epitope (GalNAc) which is recognized as non-self
by specific antibodies, forming IgA-immune complexes that
are deposited in the renal mesangium and cause glomerular
injury (78). In this example, abnormally hypoglycosylated
IgA1 is a glycophenotype associated with IgA nephropathy.
Exemplary glycophenotypes measured on biomolecules
from cells, tissues and bodily fluids are indicated in Figure 2
and Table 1. For example, assays are performed to quan-
tify and characterize free glycans, glycopeptides, glycopro-
teins and glycosyltransferase activities in body fluids (urine,
blood or serum and cerebrospinal fluid), or in cells, such as
fibroblasts. Standard glycomics assays include protein anal-
ysis via mass spectrometry, glycosyltransferase activity and
glycan binding assays. Glycophenotypes can be described in
a structured way as abnormalities of the biomolecule in a
given anatomical location, such as abnormal glycopeptide
level in the blood.
Abnormalities in the structure, abundance, location
and biological activity of glycans have been identified in
over one hundred genetic disorders, including diseases with
abnormalities of glycan degradation, congenital disorders
of glycosylation (CDG) and deglycosylation (79).Disorders
related to glycosylation often present a multitude of
molecular glycophenotypes.
Abnormal glycophenotypes are present in many genetic
diseases related to glycobiology as indicated in Table 1, but
they have also been described in the ‘fringes’ of our current
knowledge of glycan-associated genes (80). For instance,
dysfunction in the DNA excision repair enzyme encoded
by ERCC6 (excision repair 6, chromatin remodeling factor)
can lead to abnormal fucosylated glycans in the urine,
which is a marker for Cockayne syndrome type 2 (81).
Glycophenotyping to Improve Human
Disease Diagnosis: Fucosidosis
Within the Monarch Initiative platform, whereas hep-
atomegaly is a common phenotype for 494 diseases (87),
oligosacchariduria is a distinctive glycophenotype for nine
diseases (40). As unique glycophenotypes can be markers
for specific diseases, we hypothesized that expanding
the representation of glycophenotypes in the HPO and
their use in disease annotations could improve phenotype-
based comparisons. As a proof of concept,we performed an
analysis with phenotypes associated with the disease fucosi-
dosis (MONDO:0009254). We created 1000 ‘simulated’
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Figure 3. Improvement of disease diagnostic with molecular glycophenotypes for fucosidosis. Panel A lists 18 phenotypes frequently associated
with fucosidosis. The columns in Panels B and C illustrate simulated patients phenotypes profiles composed of a random selection of 10 of these 16
phenotypes. The profiles in Panel C include glycophenotypes (bottom in orange), whereas those in Panel B do not. Panel D shows that when these
two groups of 1000 simulated profiles are compared for their diagnostic utility, the profiles that contain glycophenotypes (C) significantly outperform
those that do not (B) (Fisher exact P-value = 8.5e-47). Moreover, more specific glycophenotypes are more diagnostically useful than more general
ones. This underscores the importance of harmonizing glycophenotypes across data resources as well as collecting them from patients.
patients’ profiles by randomly sampling 10 out the 16
most frequently associated phenotypes with fucosidosis
within Monarch Initiative platform (Figure 3A and B). In
a second set, we randomly replaced two phenotypes (blue
squares, Figure 3B) with two glycophenotypes known to be
associated with fucosidosis for each profile (orange squares,
Figure 3C). Both sets were compared using the PhenoDigm
algorithm (17), which given a list of phenotypes, ranks
candidate diseases based on phenotypic similarity. As
shown in Figure 3D, the addition of glycophenotypes
led to a higher ranking for fucosidosis (rank #1: 82%
with glycophenotypes versus 53% without the two
glycophenotypes with a Fisher exact P-value = 8.5e-47).
The workflow is available in a Jupyter notebook (88) at
http://bit.ly/glycop_owlsim_analysis.
This demonstrates that the addition of glycophenotypes
improves the ranking of relevant glyco-related diseases
for candidate diagnoses. Thus, we believe that broadening
the representation of molecular phenotypes in phenotype
ontologies could help refine rare disease diagnoses.
Landscape Review of Glycobiology and
Glyco-Disease Resources: A Need for
Improved Glycan Representation and
Standards
To the best leverage abnormal glycophenotype data in
bioinformatics analyses, as with metabolomics data for
the prioritization of pathological variants for whole
genome/exome sequencing (WGS/WES) (89), we need com-
prehensive, standardized and connected representations
of glycan terminology. This requirement includes interop-
erable representation of glycophenotypes in biomedical
ontologies, KBs and DBs. While the nomenclature for
glycan-related diseases is well established, the nomenclature
for glycans can be complex. We face several hurdles to
increase the standardized representation of glycopheno-
types:
(1) Lack of a unified standard terminology and identifiers
for glycans and glycan related entities (e.g. effort such
as GlycoCT (90) and the Symbol Nomenclature for
Graphical Representations of Glycans (SNFG) (91),
respectively, for encoding scheme and pictorial repre-
sentation of glycans, but they are not mandatory in all
journals).
(2) Technical/experimental barriers for interrogating gly-
cophenotypes (standardmass spectrometry cannot dif-
ferentiate monosaccharide epimers and define linkage
between monosaccharides).
(3) Lack of coverage of glycan-related concepts in ontolo-
gies (for instance, the Chemical Entities of Biological
Interest (CHEBI) ontology (92) contains 264 entries,
while more than 100000 unique cross-species and syn-
thetic glycan structures exist in the glycan repository
GlyTouCan (93) and 15000 unique glycan structures
have been estimated for humans (94)).
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(4) Lack of associations of glycans and glycan abnormali-
ties with diseases and phenotypes in existing databases
such as Monarch (12).
(5) Lack of interoperability across DBs/KBs containing
glycan-related data/knowledge (for instance, the
semantic barrier between scientific disciplines related
to glycobiology as the samemolecule can be referred to
differently in different subdisciplines of immunology,
hematology, biochemistry: CD173, blood group O,
H-type 2 antigen (95) or Fuc(α1-2)Gal(β1-4) GlcNAc
(96)).
(6) Lack of queryable data store based on glycopheno-
types, levels, location, subjects, assays, abnormalities,
evaluand, gene, etc. (e.g. an increase/decrease or pres-
ence/absence of a particular glycophenotype in a given
bodily fluid in a given genetic disease, see Figure 2).
(7) Lack of human and machine-readable formats for
diseases, glycans and phenotypes (e.g. International
Union of Pure and Applied Chemistry, IUPAC (97)).
(8) Lack of glycophenotype algorithms for disease com-
parison based on structured rules (e.g. increase of Tn
antigen associated with mutation on C1GALT1C1
for cancer (98)), logical structure and relationships
between entities (e.g. fuzzy phenotype search (13)).
Hence, there is a need for a standardized vocabulary
and identifiers, best practices to facilitate the curation of
glycophenotypes related to genetic diseases, especially as the
human glycome project aims to define the structures and
functions of human glycans which have started (99).
Regardless of this complexity, many glycobiology-
related KBs exist with differences in specificity (glycan-
related enzymes, diseases, molecules, etc.) that could be
used for disease and glycan comparisons in a human
readable and computable manner. In Table 2, we provide
a review of existing resources and identified gaps and
opportunities for additional development in both the HPO
and cross-species phenotype ontologies and glyco-KBs and
DBs. We focused particularly on diseases and/or glycans
by highlighting features, applications, uses and challenges
in order to provide potential resources for representing
glycophenotypes in a compatible way with the HPO, and
applying them toward phenotype-based patient diagnosis
and disease-gene discovery.
We reviewed a selection of widely used KBs and ontolo-
gies with glycan-related content that will help to jump the
hurdles we mentioned above. Based on these criteria, we
selected relevant KBs/services that could be used to support
ontological glycophenotype representations for phenotype-
based diagnosis and disease-gene discovery as indicated
in Table 2 with CAZY (100), Consortium for Functional
Glycomics (CFG) (101), GlyConnect (102), GlycoSciences
(103), GlyTouCan (93), Japan Consortium for Glycobiol-
ogy and Glycotechnology DataBase (JCGGDB) (104), The
Kyoto Encyclopedia of Genes and Genomes (KEGG) glycan
(105), Monarch (13), OMIM (25), Pubchem (106), Reac-
tome (107), UniLectin (108), CHEBI (92), gene ontology
(GO) (109) and NCIt (24).
Following this scope of disease-glycophenotype associa-
tion, we reviewed key features/applications, use and poten-
tial challenges (e.g. using community standards, providing
glycan identifiers, links to other resources, etc.) as indicated
in Table 3. The majority of the KBs/DBs possess human
and machine-readable formats (14/15) and standardized
terminologies (15/15) and ontologies (10/15). While all of
them have a queryable data store, only two of them possess
a phenotype algorithm (Reactome and Monarch) and one
has both raw and curated data (CFG). About 8/15 of them
have more than 1000 glycans-related terms. Therefore,
we propose to build a modular molecular glycophenotype
branch that could be integrated into the HPO and other
phenotype ontologies as shown in Figure 4.
A Comprehensive Semantic Representation
of Glycophenotypes
Integration of glycophenotypes in the HPO and
the uPheno framework—prototype of a MGPO
The initial high-level classification of molecular glycophe-
notypes is now available in HPO, for instance ‘Abnormal
protein glycosylation’ (HP:0012346) or ‘Abnormality of
glycolipid metabolism’ (HP:0010969). Future efforts will
include the integration of subclasses of glycophenotypes
in HPO using the resources described above as well as
glycan-related terms from clinical measures from the
Logical Observation Identifiers Names and Codes (LOINC)
within the context of the LOINC2HPO project (110).
As this work matures, it will be necessary to create rich
educational materials and in-line help for glycobiology
curators.
Future effort will also include a developed version of
the molecular glycophenotype ontology (MGPO) (86).
MGPO phenotypes are logically defined according to
the patterns defined by the Unified Phenotype Ontology
(uPheno) framework wherever possible (16). Complex
patterns specific to glycophenotypes (beyond the scope of
uPheno) extend existing uPheno patterns.MGPOprototype
includes the following primary characteristics (glycan
levels, composition, length, occupancy and binding) and
secondary dimensions (glycan type, attachment status,
location, residue type and residue position) (https://github.
com/monarch-initiative/glyco-phenotype-ontology) (86).
The MGPO prototype aimed to inform a more compre-
hensive ontological representation of glycophenotypes.
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Table 3. Review of KB and Ontologies We reviewed relevant knowledge bases and ontologies based on criteria such as
presence of human-machine readable, phenotype algorithms, numbers of glycan related terms, etc. Some KBs are richer
than other, nevertheless, none of them cover all the criteria
Resources Human and
machine-readable
formats
Queryable data
store
Phenotype
algorithms
Standardized
terminologies and
ontologies
Type of data Glycans-related
terms (glycan, sugar,
carbohydrate,
glycoproteins,
glycolipid,
glycosyltransferase
and lectin)
CAZY No Yes No Many Curated 333
CFG No Yes No Many Raw & curated >1000
Glyconnect Yes Yes No Many Curated >1000
GlycoSciences Yes Yes No Many Curated >1000
Glytoucan Yes Yes No Many Curated >1000
JCGGDB Yes Yes No Many Curated >1000
KEGG glycan Yes Yes No Many Curated >1000
Monarch Yes Yes Yes Many Curated 54
OMIM Yes Yes No Many Curated 227
Pubchem Yes Yes No Many Curated 252
Reactome Yes Yes Yes Many Curated 352
UniLectin No Yes No Many Curated 50
CHEBI Yes Yes No Many Curated >1000
GO Yes Yes No Many Curated >1000
NCIt Yes Yes No Many Curated 364
Considering the biochemical diversity of monosaccharides
and possible linkages (e.g. chirality of the molecules,
anomeric carbon and 2k stereoisomers, where k is the
number of carbon atoms (111)), the diversity of glycan
chains quickly becomes exponential. To enable this level of
expansion while retaining robust and consistent logical
structure, we will use ‘Dead Simple Ontology Design
Patterns’ (DOSDP) (112). Use of DOSDPs ensures the
interoperability of glycophenotype terms with those from
other phenotype ontologies and its future integration
into uPheno, currently being developed by the Monarch
Initiative and collaborators from the Phenotype Ontology
Reconciliation Effort (113).
Challenges with an ontological representation of
glycophenotypes
A robust and comprehensive glycophenotype ontological
representation would (i) provide synonyms of glycans
between disciplines (e.g. Tn antigen or O linked N-
acetylgalactosaminyl epitope or O-GalNAc (114)); (ii)
gather identifiers (GlyTouCan, Kegg, CHEBI, JCGGDB,
IUPAC, etc.); (iii) describe glycophenotypes of genetic
disease with higher granularity (e.g. increase of fucosy-
lated glycans in the urine for ERCC6 (81)); (iv) allow
comparisons between known and unknown diseases (e.g.
answering questions such as ‘what diseases show an
increase of fucosylated glycans in the urine?’); and (v)
provide phenotype terms for annotations for biocurators.
This integration will allow semantic similarity approaches
for disease diagnosis based on phenotypes, including gly-
cophenotypes, variant prioritization, patient matchmaking
and model system discovery.
However, integrating glycophenotypes in an ontology
creates some conceptual challenges that will require com-
munity discussion:
• #1 Determination of equivalence between native and
experimental glycans is challenging and will require the
harmonization of nomenclature between IUPAC, CHEBI,
GlyTouCan, etc.
• #2 Alignment of logical definitions across OBO Foundry
ontologies will be difficult due to the different glycobi-
ology modeling that is represented in different contexts,
and due to gaps. For example, CHEBI does not include
protein; therefore, there is no place for glycoproteins; the
protein ontology does not provide information about the
glycan portion of a glycoprotein other than the highest
level (e.g. N or O glycosylated); the GO represents only
biological processes and some glycobiology processes
are unknown for some phenotypes (e.g. dysfunctional
DNA repair enzyme ERCC6 is associated with increased
fucosylated glycan in the urine, yet the biological process
is unknown (81)).
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Figure 4. Potential KBs and data sources for the improvement of glycophenotypes representation for HPO and Monarch glycophenotypes related to
diseases indicated in publications and KBs could be used to enhance glycan-related knowledge in Monarch.
• #3 Some phenotypes are quantitative and would require
conversion to semantic qualitative descriptors, for exam-
ple glycan array data where there are plots of relative
fluorescence unit based on the binding of a protein to an
array of hundreds of glycans.
• #4 Full granularity of the description of glycophenotypes
could be challenging to navigate for curators, for example
increase of fucosylation glycans versus the full name
of the glycans (e.g. Neu5Ac(α2-3)Gal(β 1-4)GlcNAc(β1-
3)Gal(β 1-4)[Fuc(α1-3)]GlcNAc).
The Minimum Requirement for A Glycomics Experi-
ment, Glycomics at Expasy and GlyTouCan have joined
effort to address challenge #1 with an automatic attribution
of glycan identifiers from the mass spectrometry experi-
ments (115).Nevertheless, a unification with CHEBI will be
necessary (challenge #2). Indeed, glycan structures analyzed
by mass spectrometry can be ambiguous; for instance, an
exact hexose name and linkages can remain undetermined
because of the technological limitations. While GlyTouCan
tolerates this ambiguity, it differs from CHEBI’s standards.
For instance, a urinary trisaccharide, assumed to be three
units of glucose, can be a marker for Pompe disease (36). In
this case, contrary to CHEBI, GlyTouCan can provide an
identifier (G63977XF) regardless of undetermined linkage
between the monosaccharides. This will necessarily reveal
the gaps and lack of logical interoperability across OBO
ontologies (challenge #2), but byworking with each of these
communities, we will be able to improve glycobiology for
all contexts. Close collaboration between glycobiologists
and glycoinformaticists will be required to address chal-
lenges #3 and #4.
Towards a Glyco-Enriched Knowledge Graph
of Disease for Diagnostics and Discovery
A rich set of glycophenotypes will support the integration of
disease, pathway, gene function and numerous other biolog-
ical knowledge (Figure 5). We have begun this integration
work within the context of the Monarch knowledge graph
(Figure 4) with HPO terms that are semantically associated
with Mondo diseases, genes, GO terms, etc. Additionally,
we are performing a broader characterization and review of
glycophenotypes from the literature: for typical CDG (34),
glycan-associated diseases (for instance, disease related to
GBP such as Mannose-Binding lectin deficiency), genetic
diseases where glycans are markers (e.g. ERCC6 (81)) and
across a spectrum of animal models (mouse, zebrafish,
rat, fly, etc.). We are focusing on glycan-related knowl-
edge, such as glycans and derivatives, GBP, glycobiology-
related genes and diseases. We are also collaborating with
GlyGen (https://www.GlyGen.org/) whose aim is to gather
glycobiology-related data from multiple resources to pro-
vide data mining, sharing and dissemination of glycan-
related information, and our curation of glycophenotypes
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Figure 5. Example of omics integration with ontologies related to glycans: graph representation of the impact of a dysfunctional C1GALT1C1 on
health C1GALT1C1 encodes Cosmc, a molecular chaperone for a glycosyltransferase that initiates O-GalNac glycans synthesis (T-synthase) (127).
Dysfunctional Cosmc can lead to an improper T-synthase folding, thus abnormal O-glycans with the abnormal glycophenotype: increase of sTn/Tn
antigen (SNFG symbols, respectively, yellow square for Tn and a purple diamond/yellow square for sTn) (128). Dysfunctional Cosmc (129) can be due
to mutations or epigenetic factors, for instance the hypermethylation of C1GALT1C1’s promoter can lead to increase of sTn/Tn antigen. These two
glycophenotypes are also common in many cancers (130). Mouse models have shown that C1GALT1C1 mutation can lead to abnormal O-glycans
on platelets, generating bleeding disorders similar to Bernard-Soulier syndrome (MONDO:0009276) (131) Inflammatory bowel disease similar to
Crohn’s Colitis (132) and abnormal microbiota (133). In fact, human gut microbiota (HGM) feeds on normal MUC2 glycans (134–136). Hence, the
disruption of MUC2 glycosylation due to C1GALT1C1 mutation could potentially lead to microbiota and host physiology issue (137).
and the Monarch knowledge graph will be made available
to the GlyGen platform.
Thus far, we have limited our work on glycan repre-
sentation and integration to human genetic diseases. We
plan to extend this work to include data from bacterial
and viral glycans and lectins in the context of infectious
diseases, as attachment happens through glycans (116). For
instance, Norovirus and Parvovirus lectins bind, respec-
tively, to the glycans of ABO and P blood group antigens
in host glycans, and also, host glycans and GBPs proteins
can bind to pathogens (e.g. Neisseria gonorrhoeae (117)
andNeisseria meningitidis (118)); therefore, human genetic
variants of glycosyltransferases and lectins may play a role
in microbial/viral infection (119). We believe that semantic
integration at the molecular level as illustrated in Figure 5
(which shows a graph representation of the potential impact
of the dysfunctional gene C1GALT1C1 or COSMC) will
support mechanistic discovery and identify interventional
targets. A broader integration of glycophenotypes would,
therefore, be a valuable part of pathways analysis tools
such as Impala (120), Reactome (107) and STITCH (Search
Tool for Interacting Chemicals) (121), in support of inter-
connectingmicrobiomemetabolites. Finally, molecular phe-
notyping with glycophenotypes and pathway integration
could provide better insights toward possible treatments,
for instance, dietary supplementation of glycans or glycan-
related molecules (122).
Ontology could be a way to integrate glycophenotypes
for disease diagnosis; however, another possible approach
is to integrate glycomics data to whole genome/exome
sequencing (WES/WGS) as recently done by Ashikov
et al. (123), similarly to the metabolomics integration in
genomics (89, 124, 125). For a more systematic approach,
a new bioinformatics pipeline integrating deep molecular
glycophenotyping in WES/WGS will be needed.
In conclusion, we have discussed the importance of
glycans in health and disease, the technological and infor-
matics challenges for glycan data integration for disease
discovery research and diagnostics. We have defined the
concept of abnormal glycophenotypes, demonstrated their
usefulness in disease diagnostic pipelines with the example
of fucosidosis, proposed an integration of selected ontolo-
gies/glycoscience KBs and introduced an ontology for gly-
cophenotypes (MGPO). Finally, we urge the community
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to participate in the advancement of glycophenotype rep-
resentation and its inclusion in disease research KBs and
in clinical diagnostic settings. For instance, glycobiologists
should request new abnormal glycophenotypes terms in
HPO following the guidelines (126). Similarly, clinicians
should report them using the SNFG (91) and GlyTouCan
(93) standards. Community coordination and knowledge
integration will be critical to overcome the current knowl-
edge gap defined herein.
Glossary
CAZY carbohydrate-active enzymes
CDG congenital disorders of glycosylation
C1GALT1C1 core 1 synthase,
glycoprotein-N-acetylgalactosamine
3-beta-galactosyltransferase 1 specific chaperone 1
CFG consortium for functional glycomics
CHEBI chemical entities of biological interest
ClinGen central resource that defines the clinical
relevance of genes and variants
ClinVar public archive of interpretations of clinically
relevant variants.
DB database
ERCC6 excision repair 6, chromatin remodeling factor
Fuc fucose
Gal galactose
GalNAc N-acetylgalactosamine
GBP glycan-binding protein (lectin)
Glc glucose
GlcNAc N-acetylglucosamine
GlyConnect platform for glycoscience data
GlycoSciences KB for glycoscience data
GlyTouCan repository for glycans
GO gene ontology
HGNC Human Genome Organisation Gene
Nomenclature Committee
HMO human milk oligosaccharides
HPO human phenotype ontology
HS heparan sulfate
ID identifier
Ig immunoglobulin
IUPAC International Union of Pure and Applied
Chemistry
JCGGDB Japan Consortium for Glycobiology and
Glycotechnology DataBase
KB knowledge base
KEGG Kyoto Encyclopedia of Genes and Genomes
LOINC logical observation identifiers names and codes
LPS lipopolysaccharide
MGPO Molecular GlycoPhenotype Ontology
Mondo Monarch Disease Ontology
MP Mammalian Phenotype Ontology
NCIt National Center Institute thesaurus
Neu5Ac N-acetylneuraminic acid
NIH the National Institutes of Health
OBO open biological and biomedical ontology
OMIM Online Mendelian Inheritance in Man
Orphanet KB on rare diseases
PRO protein ontology
Pubchem NIH’s chemistry KB
Reactome pathway KB
SNFG symbol nomenclature for glycans
SNOMED CT Systematized Nomenclature of Medicine
Clinical Terms
STITCH search tool for interacting chemicals
UDP Undiagnosed Diseases Program
UDN Undiagnosed Diseases Network
UniLectin KB for glycan-binding protein
uPheno unified phenotype ontology
WES whole exome sequencing
WGS whole genome sequencing
Supplementary data
Supplementary data are available at Database Online.
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